Story perspectives

FDA Strips Testosterone Heart Warning, Calls for Cancer Research

7/16/2026

Summary

Story summary

FDA removed the warning on risks for testosterone after a 2023 study found no cardiovascular increase.
Donald Trump's administration asked the FDA to rewrite testosterone prescribing instructions for symptoms, easing labeling.
Researchers Dr. Shalender Bhasin welcome the change but urge 15- to 20-year prostate cancer studies.
A 2022 analysis found only one in seven providers screened patients before prescribing testosterone, prompting societies to advise men planning fertility to avoid drug.

1 of 1

Story summary

FDA removed the warning on risks for testosterone after a 2023 study found no cardiovascular increase.
Donald Trump's administration asked the FDA to rewrite testosterone prescribing instructions for symptoms, easing labeling.
Researchers Dr. Shalender Bhasin welcome the change but urge 15- to 20-year prostate cancer studies.
A 2022 analysis found only one in seven providers screened patients before prescribing testosterone, prompting societies to advise men planning fertility to avoid drug.